Achieves positive results in pilot human study assessing blood
pressure measurement capabilities from a Rockley-powered wrist-worn
device, setting the stage for larger study
Demonstrates signal quality and measurement technique capable of
potentially providing a new continuous measurement technique for
cardiovascular health
Advances readiness of Rockley sensing platform’s broad biomarker
detection capabilities for Rockley’s customer base of 17 leading
global consumer electronics and medical device companies
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced that the company has
successfully completed the first stage of its human studies
examining the measurement of blood pressure using Rockley’s
biomarker sensing platform.
In this pilot study, Rockley researchers have demonstrated that
a photonics-based sensor worn on the wrist can measure blood
pressure non-invasively. Instead of applying a blood pressure cuff,
which can be awkward or inconvenient and cause discomfort for some,
Rockley’s wearable wrist-worn solution has the potential to provide
hassle-free, clinical-grade data about key cardiovascular
indicators.
The Rockley blood pressure sensing device used in the study
features a unique laser-based approach and advanced algorithms
employing Rockley’s cloud and AI capabilities. The signals produced
by the Rockley sensor were compared directly with signals produced
at the same time and location by an off-the-shelf
photoplethysmography (PPG) module, which employs green
light-emitting diodes (LED) and is the technology employed by most
wearables on the market today, often with the aid of a blood
pressure cuff for calibration. The signals from the Rockley sensor
were shown to provide stronger correlation with the control blood
pressure readings from a cuff than standard green-LED PPG
signals.
In addition to demonstrating blood pressure measurement, the
study showed that Rockley’s wrist-based sensing platform produces a
strong correlation of heart rate (HR) and heart rate variability
(HRV) measurement with results from commonly used electrocardiogram
(ECG) equipment.
Rockley’s in-house blood pressure studies are part of a
continuing slate of human studies designed to evaluate and refine
the performance of Rockley’s biomarker sensing platform in
measuring a wide range of biomarkers, including core body
temperature, blood pressure, body hydration, alcohol, lactate, and
glucose trends. The blood pressure study, which was conducted under
IRB approval by the WIRB-Copernicus Group Institutional Review
Board (WCG IRB), involved multiple measurements from 40 human
subjects resulting in over 480 total readings.
“Following the recent success of our core body temperature
studies, the results of our pilot blood pressure study using
wrist-based measurement are extremely encouraging,” said Dr. Hooman
Abediasl, senior vice president of product engineering at Rockley.
“These positive results represent a huge step forward in validating
our sensing solution and its ability to deliver powerful
multi-biomarker functionality in a highly manufacturable wearable
form factor.”
Rockley announced its biomarker sensing platform in the summer
of 2021. Since the announcement, the Rockley sensing platform has
continued to gain significant traction in both the consumer and
medtech markets. To date, Rockley has contracted with seventeen
leading global manufacturers: twelve global consumer electronics
customers, including six of the top-ten players in the wearables
market, and five medical device companies, including two of the
top-ten players in the medical equipment space.
“Demonstrating the ability to measure blood pressure from a
wrist-worn device is essential in the development of our biosensing
platform, for us and for our growing customer base,” added Dr.
Andrew Rickman, chief executive officer and founder of Rockley.
“This study represents a critical step towards achieving our goal
of measuring multiple biomarkers. Even more exciting is that the
results from this study have demonstrated a quality of both signal
and measurement techniques that have the potential to enable a new
class of cardiovascular health monitoring. Whether in consumer
wearables or medtech, our customers understand that the ability to
measure blood pressure from a wristband or smartwatch could have an
enormous impact on personal healthcare.”
Rockley believes that the combination of its sensing technology
and its cloud and artificial intelligence (AI) infrastructure can
provide better information for healthcare providers and greater
peace of mind for patients, athletes, and people anywhere who’d
like meaningful insights into their health and well-being.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/biomarker-sensing.
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “allow,” “anticipate,”
“believe,” “can,” “capability,” “continue,” “could,” “develop,”
“enable,” “estimate,” “eventual,” “expand, “expect,” “focus,”
“forward,” “future,” “goal,” “intend,” “may,” “might,”
“opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “realize,” “revolutionize,”
“seem,” “should,” “trend,” “vision,” “will,” “would” or other terms
that predict or indicate future events, trends, or expectations,
and similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
potential of Rockley’s sensing platform to provide real-time
insights and clinical grade data about a variety of health
conditions, including cardiovascular health, and monitor blood
pressure, heart rate and heart rate variability from a wearable
device; (b) the importance of the ability to monitor key biomarkers
like blood pressure on a continuous basis; (c) the potential impact
of the ability to miniaturize the monitoring of key biomarkers into
a tiny form factor; (d) the potential to leverage data collected
from Rockley’s biomarking sensing products to enable additional
capability for the fast-growing digital health domain; (e) the
potential effectiveness of the wearable sensing platform for
determining key biomarkers, including blood pressure, heart rate
and heart rate variability; (f) the expectation that the
cloud-based analytics and AI capabilities of Rockley’s platform can
help develop a more holistic assessment of a person’s health and
well-being; (g) Rockley’s belief that its cloud and AI
infrastructure can provide better information for healthcare
providers and greater peace of mind for people who’d like
meaningful insights into their health and well-being; and (h) the
anticipated and potential features, scope, goals, and benefits of
the Company’s platform, products, and technology.
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond Rockley’s control) or other
assumptions that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the following: (i) Rockley’s ability to achieve
customer acceptance and commercial production of its products and
technology, including in a timely and cost-effective manner; (ii)
Rockley’s ability to achieve customer design wins and convert
memoranda of understanding and development contracts into
production contracts; (iii) risks related to purchase orders,
including the lack of long-term purchase commitments, the
cancellation, reduction, delay, or other changes in customer
purchase orders, and if and to the extent customers seek to enter
into licensing arrangements in lieu of purchases; (iv) Rockley’s
history of losses and need for additional capital and its ability
to access additional financing to support its operations and
execute on its business plan, as well as the risks associated
therewith; (v) legal and regulatory risks; (vi) risks associated
with its fabless manufacturing model and dependency on third-party
suppliers; (vii) Rockley’s reliance on a few significant customers
for a majority of its revenue and its ability to expand and
diversify its customer base; (viii) Rockley’s financial
performance; (ix) the impacts of COVID-19 on Rockley, its customers
and suppliers, its target markets, and the global economy; (x)
Rockley’s ability to successfully manage growth and its operations
as a public company; (xi) fluctuations in Rockley’s stock price and
Rockley’s ability to maintain the listing of its ordinary shares on
the NYSE; (xii) Rockley’s ability to anticipate and respond to
industry trends and customer requirements; (xiii) changes in the
current and future markets in which Rockley is or may be engaged;
(xiv) risks related to competition and intellectual property; (xv)
market opportunity and demand for Rockley’s products and
technology, as well as the customer products into which Rockley’s
products and technology are incorporated; (xvi) risks related to
international operations; (xvii) risks related to cybersecurity,
privacy, and infrastructure; (xviii) risks related to financial and
accounting matters; (xix) general economic, financial, political,
and business conditions, both domestic and foreign; (xx) Rockley’s
ability to realize the anticipated benefits of its recently
completed business combination with SC Health Corporation; and
(xxi) Rockley’s ability to realize the anticipated benefits of
strategic partnerships, as well as other factors described under
the heading “Risk Factors” in Rockley’s quarterly report on Form
10-Q for the quarter ended September 30, 2021, and in other
documents Rockley files with the Securities and Exchange Commission
in the future.
The forward-looking statements contained in this press release
are based on various assumptions, whether or not identified in this
press release, and on Rockley’s current expectations, beliefs, and
assumptions and are not predictions of actual performance. If any
of these risks or uncertainties materialize, or should any of these
assumptions prove incorrect, actual results may differ materially
from those discussed in or implied by these forward-looking
statements. There can be no assurance that future developments
affecting Rockley will be those that have been anticipated. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005414/en/
Media Debra Raine RaineMakers Telephone: +1 415-349-7432 Email:
rockley-pr@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Jan 2025 to Feb 2025
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Feb 2024 to Feb 2025
